Drug Resistance

Ramoplanin Study to Prevent Infection Due to Vancomycin-Resistant Enterococcus Begins Enrollment

Published in Cancer Weekly, July 25th, 2000

IntraBiotics Pharmaceuticals, Inc. (IBPI), Mountain View, California, said that it has begun patient enrollment for the Phase III clinical trial for Ramoplanin Oral.

The trial is designed to demonstrate whether treatment with Ramoplanin reduces the incidence of bloodstream infections due to Vancomycin-Resistant Enterococcus (VRE) in cancer patients known to carry VRE bacteria in their intestines.

The Ramoplanin trial is IntraBiotics' second Phase III clinical trial initiated this year. On May 4, 2000, the company announced it had begun a Phase III trial for its Protegrin IB-367 Oral Rinse, an antibiotic intended to reduce the severity of oral...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry